The Comprehensive Transplant Center at The Ohio State University Wexner Medical Center has one of the largest organ transplant programs in the nation, ranking in the top 20 for liver transplant volume, while maintaining a first year patient survival rate of 94%. Noteworthy innovations include ex-vivo liver perfusion, split liver transplantation, a living liver donor program and the ability to transplant hepatitis C-positive livers.
Ohio State Wexner Medical Center surgeons have performed 1,450 liver transplants since their first-in-Ohio liver transplant in 1984. From 2016 to 2020, volume growth accelerated nearly 280%—increasing from 39 to 148 procedures annually under the leadership of Ken Washburn, MD, division director of Transplant Surgery and executive director of Ohio State’s Comprehensive Transplant Center (CTC).
Ohio State Wexner Medical Center’s current 94.42% first-year survival rate is higher than the national rate of 93.92%, as collected by the Scientific Registry for Transplant Recipients (SRTR). The Comprehensive Transplant Center's CTC median wait time for a liver is 5.7 months, compared to the regional median of 6.5 months (updated July 6, 2021).
In addition to these outstanding volume and patient outcome metrics, the liver transplantation program at the Ohio State is one of only three locations in Ohio able to perform adult living liver donor transplants. We're also one of only 55 comprehensive cancer centers in the nation, as designated by the National Cancer Institute, and are experts in treating hepatocellular carcinoma and in preparing these patients for liver transplantation. Ohio State Wexner Medical Center also serves as a training site for liver transplant hepatologists.
Recent Ohio State program milestones include:
- First split liver transplant in 2017
- Establishment of a living liver donor program in 2018
- First heart-liver transplant in 2019
- Status as one of the few transplant centers performing normothermic ex-vivo liver perfusion, a process that enables transplantation of donated livers that were once considered unusable, thus expanding the donor pool
- Membership in the Acute Liver Failure Study group, a NIH/NIDDK funded collaborative network of hospitals that has studied more than 3,000 cases of acute liver failure
- Current clinical trials span the spectrum of liver disease and include new treatment approaches for decompensated liver disease, hepatocellular carcinoma and fatty liver disease among others.
You can find a comprehensive overview of the Ohio State Wexner Medical Center liver transplant program here.